<DOC>
	<DOC>NCT01751321</DOC>
	<brief_summary>Glucose Variability With DPP-4 Inhibition</brief_summary>
	<brief_title>Glucose Variability With DPP-4 Inhibition</brief_title>
	<detailed_description>Patients with Type 2 Diabetes, age 35-75y., will be included in this double blind randomized placebo controlled study. The sample size of 50 patients completing the 30 day study period is based on statistical input from Merck Research Laboratories, Rahway NJ.</detailed_description>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Type 2 diabetes receiving a stable dose of metformin â‰¥ 1500 mg HbA1c 7,5% 10/0 % Type 1 diabetes HbA1c &lt; 7,5% and &gt; 10,0%</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>